Brief: Otsuka Pharmaceutical And H. Lundbeck Say U.S. FDA Accepted New Drug Application For Aripiprazole Injectable To Treat Adult Schizophrenia And Bipolar I Disorder
13/09/2022 07:27
Sept 13 (Reuters) -
* OTSUKA PHARMACEUTICAL AND H. LUNDBECK SAY U.S. FDA
ACCEPTED NEW
DRUG APPLICATION FOR ARIPIPRAZOLE INJECTABLE TO TREAT ADULT
SCHIZOPHRENIA AND BIPOLAR I DISORDER
Further company coverage: 4578.T
(Reporting by Tokyo Newsroom)
((+81345201189;))
Recent news on H Lundbeck A/S
See all newsEurope Research Roundup: BAWAG Group, Enka Insaat, Partners Group Holding
Brief: CMS Announces Selection Of Drugs For Third Cycle Of The Medicare Drug Price Negotiation Program
Europe Research Roundup: BNP Paribas, Swedbank, Volkswagen
H Lundbeck steps down from takeover for Avadel, shares rise 3%
Brief: H Lundbeck A/S Says Noted That Our Offer For Acquiring Avadel No Longer Is Considered Superior By Their Board, We Are Currently Considering Our Options